$1.24
2.90% today
Nasdaq, Apr 02, 09:20 pm CET
ISIN
US29479A1088
Symbol
ERAS
Sector
Industry

Erasca Inc Stock price

$1.21
-0.08 5.86% 1M
-1.39 53.47% 6M
-1.31 51.99% YTD
-0.96 44.21% 1Y
-7.25 85.74% 3Y
-16.23 93.09% 5Y
-16.23 93.09% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
-0.17 12.04%
ISIN
US29479A1088
Symbol
ERAS
Sector
Industry

Key metrics

Market capitalization $341.34m
Enterprise Value $94.92m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 0.81
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-157.09m
Free Cash Flow (TTM) Free Cash Flow $-109.48m
Cash position $298.31m
EPS (TTM) EPS $-0.75
P/E forward negative
Short interest 13.27%
Show more

Is Erasca Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Erasca Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Erasca Inc forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Erasca Inc forecast:

Buy
100%

Financial data from Erasca Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 3.77 3.77
1% 1%
-
-3.77 -3.77
1% 1%
-
- Selling and Administrative Expenses 34 34
13% 13%
-
- Research and Development Expense 115 115
11% 11%
-
-153 -153
11% 11%
-
- Depreciation and Amortization 3.77 3.77
1% 1%
-
EBIT (Operating Income) EBIT -157 -157
11% 11%
-
Net Profit -162 -162
29% 29%
-

In millions USD.

Don't miss a Thing! We will send you all news about Erasca Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Erasca Inc Stock News

Neutral
GlobeNewsWire
8 days ago
Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Erasca will also present potential first-in-class examples of direct SMP complex inhibitors, representing a new approach to block the RAS/MAPK pathway SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly...
Neutral
GlobeNewsWire
13 days ago
Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025
Neutral
GlobeNewsWire
2 months ago
SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim Securities SMID Cap Biotech Conference being held at the Lotte New York Palace in New York, New Yor...
More Erasca Inc News

Company Profile

Erasca, Inc. is a clinical stage precision oncology company that focuses on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim on July 2, 2018 and is headquartered in San Diego, CA.

Head office United States
CEO Jonathan Lim
Employees 103
Founded 2018
Website www.erasca.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today